Bernstein Initiates Coverage On Pacific Biosciences with Outperform Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst Eve Burstein has initiated coverage on Pacific Biosciences (NASDAQ:PACB) with an Outperform rating and a price target of $11.
September 28, 2023 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pacific Biosciences has been given an Outperform rating and a price target of $11 by Bernstein analyst Eve Burstein.
The Outperform rating and price target of $11 by Bernstein analyst Eve Burstein indicates a positive outlook for Pacific Biosciences. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100